Rexulti brexpiprazole APPROVED
Drug Profile
ModalitySmall molecule
RouteORAL
Therapy AreaNeurology
Launch2015-07-10
Peak Sales Est$3000M
Formulations[{"id":"rexulti-oral","route":"ORAL","device":"Tablet (0.25mg, 0.5mg, 1mg, 2mg, 3mg, 4mg)","setting"
Companies
4578 (ORIGINATOR)55%
LUN (CO_DEVELOPER)45%
Mechanism: Serotonin-Dopamine Activity Modulator (SDAM)
Expert: Partial agonist at dopamine D2/D3 and serotonin 5-HT1A receptors with antagonism at 5-HT2A receptors. Stabilizes dopaminergic and serotonergic neurotransmission by acting as a functional agonist in hypodopaminergic states and antagonist in hyperdopaminergic states.
Everyday: Fine-tunes dopamine and serotonin signals in the brain — like a thermostat that adjusts these chemical messengers up or down depending on what the brain needs, rather than simply turning them on or off.
Targets: []
Revenue History
PeriodRevenue ($M)
2024$1,800M
2025$2,200M
Programs (4)
IndicationStageKey StudyRegional Status
SchizophreniaAPPROVEDPhase 3 (BEACON/Vector)[{"stage":"APPROVED","region":"US","approval_date":"2015-07-10"},{"stage":"APPRO
MDD adjunctiveAPPROVEDPyxis/Polaris[{"stage":"APPROVED","region":"US","approval_date":"2015-07-10"}]
Alzheimer's agitationAPPROVEDPhase 3 (Study 331-14-213)[{"stage":"APPROVED","region":"US","approval_date":"2023-05-11"},{"stage":"APPRO
PTSDPHASE3Phase 3 PTSD studies[]
Data from Supabase · Updated 2026-03-24